Orforglipron liver safety: pooled data

Orforglipron is not a peptide, and that is why its liver data got a paper of its own. Semaglutide and tirzepatide are modified hormones, broken down by proteolysis and cleared largely through the kidneys. Orforglipron is a small molecule metabolised through the liver^[1]. A pooled analysis of 11,220 participants across seven phase 3 orforglipron trials, published in Diabetes, Obesity and Metabolism in 2026, found no confirmed case of drug-induced liver injury and no case meeting Hy's Law criteria^[1].

Why liver safety is a small-molecule question

Most approved GLP-1 receptor agonists are peptides, injected, cleared by proteolysis and renal elimination^[1]. Orforglipron reaches the same receptor by a different chemical route. It is a daily tablet, metabolised mainly through the liver, and in laboratory assays it inhibits hepatic transporters including OATP1B, BSEP and MRP2^[1]. The authors argue those effects occur at concentrations far above anything a patient reaches, but the metabolic route alone puts the liver under closer watch.

There is precedent for the worry. Pfizer's lotiglipron, a once-daily small-molecule GLP-1 agonist, was dropped in 2023 after phase 1 work showed liver enzyme elevations^[3]. A 2026 review in Frontiers in Pharmacology puts the lesson plainly: these molecules share a target, but they do not share one hepatic risk profile^[3].

What the analysis pooled

The safety population was 11,220 randomised people who took at least one dose across seven phase 3 trials: ATTAIN-1 and ATTAIN-2 in weight management, ACHIEVE-1 through ACHIEVE-5 in type 2 diabetes. Of those, 6,920 received orforglipron and 4,300 a comparator: placebo, oral semaglutide at 7 mg or 14 mg, dapagliflozin 10 mg, or insulin glargine by trial^[1]. Follow-up ran to 104 weeks, covering 8,889 patient-years of orforglipron exposure^[1].

Liver chemistry was drawn every 4 to 12 weeks depending on the trial. Anyone crossing a prespecified threshold was reviewed by two blinded safety physicians from a different therapeutic area, with a hepatologist as tiebreaker^[1].

The bar they were testing against is Hy's Law, set out in the FDA's 2009 guidance on premarketing evaluation of drug-induced liver injury. A case needs three things together: ALT or AST at least three times the upper limit of normal, total bilirubin above twice the upper limit without cholestasis, and no other explanation. The guidance calls one such case worrying and two highly predictive of severe liver injury after launch^[4].

The numbers

Six orforglipron participants (0.1%) and six comparator participants (0.1%) hit that enzyme and bilirubin combination. All six orforglipron cases had another cause on review: two gallstone disease, one acute hepatitis A infection, two with indirect hyperbilirubinaemia alongside alcohol use or Gilbert's syndrome, and one tied to herbal medicine with Gilbert's syndrome^[1]. None was adjudicated as drug-induced liver injury.

Categorical enzyme elevations sat close together. ALT at three times the upper limit of normal or higher occurred in 142 orforglipron participants (2.1%) against 80 comparator participants (1.9%), and ALT at ten times or higher in 16 (0.2%) against 6 (0.1%)^[1]. Most orforglipron cases at that top threshold had alternative causes recorded.

Average enzyme levels moved down rather than up. In ACHIEVE-3, the registered head-to-head against oral semaglutide^[6], ALT fell 22.8% on orforglipron 9 mg and 28.7% on orforglipron 17.2 mg by week 52, against 15.9% and 22.0% on oral semaglutide 7 mg and 14 mg^[1]. The authors read that as the liver responding to weight loss, not to the drug.

Reported hepatic adverse events were balanced at 315 orforglipron participants (4.6%) against 187 on comparators (4.4%), mostly enzyme abnormalities rather than clinical liver disease. Serious hepatic events were rarer on orforglipron, 5 cases (0.07%) against 7 (0.16%)^[1].

One number did not sit flat. Gallstones were reported in 1.0% of orforglipron participants against 0.6% of comparators, though gallbladder inflammation rates were similar and nobody was screened at baseline^[1].

What the analysis does not settle

This is company evidence. Eli Lilly funded the work, five of the six authors are Lilly employees and shareholders, and the sponsor designed the trials, ran the statistics and supplied medical writing support^[1]. The adjudicating physicians were blinded and drawn from an unrelated therapeutic area, but they too were Lilly employees^[1].

The population was filtered first. Anyone with ALT or AST above five times the upper limit of normal was excluded, as was anyone with liver disease other than fatty liver. Three of the seven trials were open-label, which the authors flag as possible bias in how hepatic events got reported. Steatosis and fibrosis were never imaged or biopsied, so a falling ALT is an inference about liver inflammation, not a measurement of it^[1].

Sample size matters as well. Roughly 7,000 people took the drug here, and an injury occurring once in 20,000 exposures would not surface in a database that size. The Frontiers review notes the FDA approval letter carries a post-marketing commitment to evaluate drug-induced liver injury^[3].

The US label reflects the same reading. When the FDA approved orforglipron as Foundayo for weight management on 1 April 2026, the warnings covered pancreatitis, severe gastrointestinal reactions, acute kidney injury, gallbladder disease and diabetic retinopathy, plus a boxed warning for thyroid C-cell tumours. Liver injury is not on the list^[2].

What this means for the pill comparison

For a reader choosing between the two oral GLP-1 options, liver safety is not the deciding variable. Oral semaglutide is authorised in the EU as Rybelsus for type 2 diabetes^[5], and this analysis puts orforglipron's hepatic profile alongside it, not behind it^[1]. What separates them is blood sugar control and tolerability, covered in our read of the ACHIEVE-3 head-to-head.

What the paper does support is narrower than the headline. The small-molecule worry raised by lotiglipron has been answered for this one molecule, at these doses, over this length of follow-up. It has not been answered for the class, and the authors do not claim it has.

Licensing differs by country and orforglipron's approvals are moving fast. Our semaglutide regulation page tracks where the peptide comparator stands. This article is for educational and journalistic purposes and is not medical advice. Anyone with existing liver disease considering a GLP-1 medicine should raise that history with their prescribing clinician.

What we don't yet know

Whether the ALT reductions mean anything under a microscope is still open. The authors say dedicated trials in fatty liver disease and steatohepatitis are needed to separate improved inflammation from a number that simply moved^[1]. There is also no liver data above five times the upper limit of normal at baseline, nothing past 104 weeks, and no analysis run outside the sponsor. Our earlier explainer on orforglipron in obesity covers what the efficacy side is still missing, cardiovascular outcomes included. For the semaglutide safety record the comparison base is far longer.